Consensus TransMedics Group, Inc.

Equities

TMDX

US89377M1099

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
92.08 ^USD	+3.17%		+9.41%	+16.66%

04-18	Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing	MT
04-05	Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing	MT

Evolution of the average Target Price on TransMedics Group, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5717f92147aa522.bmYwWSCbIfODpmBUi_cuQNYbtF_GjskHoYVqqaaERuQ.FldZLlL5FarV_1UZzpwcCu9x3RKP9qNQ0N04_8DKN7UIL3M-Zf5RntrhFw~595420e70ba0413f861d08d8558eba89

Analyst Recommendations on TransMedics Group, Inc.

Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing	04-18	MT
Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing	04-05	MT
Transmedics Group Insider Sold Shares Worth $1,110,150, According to a Recent SEC Filing	04-02	MT
Piper Sandler Initiates TransMedics Group With Overweight Rating, $95 Price Target	03-28	MT
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating	02-27	MT
Morgan Stanley Adjusts TransMedics Group Price Target to $75 From $54, Maintains Equal Weight Rating	12-04	MT
Morgan Stanley Adjusts Price Target on TransMedics to $54 From $50, Maintains Equal-Weight Rating	11-07	MT
Waning Optimism on Rate Cuts Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	11-07	MT
Earnings, Rates Blunt Wall Street Pre-Bell; Asia Down Europe Flat	11-07	MT
Morgan Stanley Adjusts Price Target on TransMedics Group to $50 From $81, Keeps Equalweight Rating	13/10/23	MT
Morgan Stanley Adjusts Price Target on TransMedics to $50 From $81, Maintains Equal-Weight Rating	13/10/23	MT
Oppenheimer Adjusts TransMedics Group Price Target to $92 From $90, Maintains Outperform Rating	04/08/23	MT
William Blair Initiates TransMedics at Outperform	19/07/23	MT
Canaccord Genuity Adjusts Price Target on TransMedics to $86 From $91, Maintains Buy Rating	18/05/23	MT
Morgan Stanley Adjusts Price Target on TransMedics Group to $81 From $74, Maintains Equalweight Rating	03/05/23	MT
Oppenheimer Adjusts TransMedics Price Target to $90 From $85, Maintains Outperform Rating	02/05/23	MT
JPMorgan Stanley Adjusts TransMedics Group's Price Target to $81 From $67, Keeps Overweight Rating	23/02/23	MT
Morgan Stanley Adjusts TransMedics Group's Price Target to $74 From $63, Keeps Equalweight Rating	23/02/23	MT
Cowen Adjusts TransMedics Group's Price Target to $75 From $70, Keeps Outperform Rating	23/02/23	MT
Canaccord Genuity Adjusts Price Target on TransMedics to $78 From $68, Maintains Buy Rating	23/02/23	MT
Oppenheimer Adjusts TransMedics Group's Price Target to $85 From $55, Maintains Outperform Rating	23/02/23	MT
Morgan Stanley Adjusts TransMedics Group's Price Target to $63 From $54, Keeps Equalweight Rating	06/01/23	MT
Morgan Stanley Adjusts TransMedics Group Price Target to $63 From $54, Maintains Equal Weight Rating	06/01/23	MT
Oppenheimer Adjusts TransMedics Group Price Target to $55 From $45, Maintains Outperform Rating	04/11/22	MT
Morgan Stanley Adjusts TransMedics Group's Price Target to $45 from $37, Keeps Equalweight Rating	11/10/22	MT